Pheon Therapeutics, an Antibody-Drug Conjugate (ADC) specialist situated in Harpenden, near London, UK, has secured a $120 million Series B funding. The company is developing next generation ADCs for a variety of hard-to-treat malignancies.
Investors
- TCGX
- Atlas Venture
- Brandon Capital
- Forbion
- Research Corporation Technologies
- BVF Partners
- Lightspeed
- Perceptive Advisors
- Cariad Chester
- Managing Partner of TCGX, will become a member of the board of directors as part of the funding.
Use of funds
With clinical proof of concept, the business plans to further develop its unique ADC pipeline and increase the range of internal technological platforms it uses to create optimal ADC constructions.
About Pheon Therapeutics
Pheon Therapeutics, an expert in antibody drug conjugates (ADCs) and solid tumor treatment, is spearheading the development of a pipeline of ADCs based on innovative targets and linker payloads under the direction of CEO Cyrus Mozayeni, MD. The flagship product of Pheon is a first-in-class ADC directed against a new target that is greatly overexpressed in a variety of cancer types that are difficult to treat.
The business anticipates moving quickly toward dosage expansion cohorts, with its first Phase 1 clinical trial scheduled to begin in 2024.
